TGFB1 and breast carcinoma: In this regard, the angiotensin receptor blocker (ARB) losartan can significantly reduce the secretion of collagen and HA by CAFs through inhibiting TGF-β1-mediated pro-fibrotic signaling, thereby improving tumor vascular perfusion and drug delivery efficiency [231], enhancing the effects of chemotherapy, radiotherapy, and immunotherapy [189, 232–234], and significantly inhibiting breast cancer progression [235].